Two separate developments intensified scrutiny of trial conduct and disclosure in high-impact oncology publishing. A Nature Medicine retraction targeted a high-profile China-led lung cancer study, while the NEJM retraction of Amgen’s Tavneos pivotal trial cited re-adjudication of primary endpoint assessments after database lock and unblinding—an issue not disclosed in the original publication. Together, the moves add momentum to regulators’ and journals’ efforts to tighten systems for verifying clinical claims and maintaining transparency.